Literature DB >> 20525460

Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project.

R Baker1, I Bateman, C Donaldson, M Jones-Lee, E Lancsar, G Loomes, H Mason, M Odejar, J L Pinto Prades, A Robinson, M Ryan, P Shackley, R Smith, R Sugden, J Wildman.   

Abstract

OBJECTIVES: To identify characteristics of beneficiaries of health care over which relative weights should be derived and to estimate relative weights to be attached to health gains according to characteristics of recipients of these gains (relativities study); and to assess the feasibility of estimating a willingness-to-pay (WTP)-based value of a quality-adjusted life-year (QALY) (valuation study).
DESIGN: Two interview-based surveys were administered - one (for the relativities study) to a nationally representative sample of the population in England and the other (for the valuation study) to a smaller convenience sample.
SETTING: The two surveys were administered by the National Centre for Social Research (NatCen) in respondents' homes. PARTICIPANTS: 587 members of the public were interviewed for the relativities study and 409 for the valuation study.
METHODS: In the relativities study, in-depth qualitative work and considerations of policy relevance resulted in the identification of age and severity of illness as relevant characteristics. Scenarios reflecting these, along with additional components reflecting gains in QALYs, were presented to respondents in a series of pairwise choices using two types of question: discrete choice and matching. These questions were part of a longer questionnaire (including attitudinal and sociodemographic questions), which was administered face to face using a computer-assisted personal interview. In the valuation study, respondents were asked about their WTP to avoid/prevent different durations of headache or stomach illness and to value these states on a scale (death = 0; full health = 1) using standard gamble (SG) questions.
RESULTS: Discrete choice results showed that age and severity variables did not have a strong impact on respondents' choices over and above the health (QALY) gains presented. In contrast, matching showed age and severity impacts to be strong: depending on method of aggregation, gains to some groups were weighted three to four times more highly than gains to others. Results from the WTP and SG questions were combined in different ways to arrive at values of a QALY. These vary from values which are in the vicinity of the current National Institute for Health and Clinical Excellence (NICE) threshold to extremely high values.
CONCLUSIONS: With respect to relative weights, more research is required to explore methodological differences with respect to age and severity weighting. On valuation, there are particular issues concerning the extent to which 'noise' and 'error' in people's responses might generate extreme and unreliable figures. Methods of aggregation and measures of central tendency were issues in both weighting and valuation procedures and require further exploration.

Entities:  

Mesh:

Year:  2010        PMID: 20525460     DOI: 10.3310/hta14270

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN: 1366-5278            Impact factor:   4.014


  32 in total

Review 1.  Establishing disability weights from pairwise comparisons for a US burden of disease study.

Authors:  Jürgen Rehm; Ulrich Frick
Journal:  Int J Methods Psychiatr Res       Date:  2013-05-28       Impact factor: 4.035

2.  Choosing vs. allocating: discrete choice experiments and constant-sum paired comparisons for the elicitation of societal preferences.

Authors:  Chris D Skedgel; Allan J Wailoo; Ron L Akehurst
Journal:  Health Expect       Date:  2013-06-12       Impact factor: 3.377

3.  Valuing health at the end of life: an empirical study of public preferences.

Authors:  Koonal K Shah; Aki Tsuchiya; Allan J Wailoo
Journal:  Eur J Health Econ       Date:  2013-05-09

4.  Value of a QALY and VSI estimated with the chained approach.

Authors:  S Olofsson; U-G Gerdtham; L Hultkrantz; U Persson
Journal:  Eur J Health Econ       Date:  2019-06-06

5.  Measuring the end-of-life premium in cancer using individual ex ante willingness to pay.

Authors:  S Olofsson; U-G Gerdtham; L Hultkrantz; U Persson
Journal:  Eur J Health Econ       Date:  2017-08-12

6.  NICE's cost-effectiveness range: should it be lowered?

Authors:  J P Raftery
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

Review 7.  2016 reflections on the favorable cost-benefit of lung cancer screening.

Authors:  Bruce Pyenson; Gabriela Dieguez
Journal:  Ann Transl Med       Date:  2016-04

Review 8.  Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.

Authors:  Tatjana E MacLeod; Anthony H Harris; Ajay Mahal
Journal:  Patient       Date:  2016-06       Impact factor: 3.883

9.  Unchained melody: revisiting the estimation of SF-6D values.

Authors:  Benjamin M Craig
Journal:  Eur J Health Econ       Date:  2015-09-10

Review 10.  A systematic review of stated preference studies reporting public preferences for healthcare priority setting.

Authors:  Jennifer A Whitty; Emily Lancsar; Kylie Rixon; Xanthe Golenko; Julie Ratcliffe
Journal:  Patient       Date:  2014       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.